|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C显示文摘AIM:To construct formulae for predicting the likelihood of ribavirin-induced anemia in pegylated interferon plus ribavirin for chronic hepatitis C.METHODS:Five hundred and sixty-one Japanese patients with hepatitis C virus genotype 1b who had received combination treatment were enrolled and assigned randomly to the derivation and confirmatory groups.Single nucleotide polymorphisms at or nearby ITPA were genotyped by real-time detection polymerase chain reaction.Factors influencing significant anemia(hemoglobin concentration < 10.0 g/dL at week 4 of treatment) and significant hemoglobin decline(declining concentrations > 3.0 g/dL at week 4) were analyzed using multiple regression analyses.Prediction formulae were constructed by significantly independent factors.RESULTS:Multivariate analysis for the derivation group identified four independent factors associated with significant hemoglobin decline:hemoglobin decline at week 2 [P = 3.29 × 10-17,odds ratio(OR) = 7.54(g/dL)],estimated glomerular filtration rate [P = 2.16 × 10-4,OR = 0.962(mL/min/1.73 m 2)],rs1127354(P = 5.75 × 10-4,OR = 10.94) and baseline hemoglobin [P = 7.86 × 10-4,OR = 1.50(g/dL)].Using the model constructed by these factors,positive and negative predictive values and predictive accuracy were 79.8%,88.8% and 86.2%,respectively.For the confirmatory group,they were 83.3%,91.0% and 88.3%.These factors were closely correlated with significant anemia.However,the model could not be constructed,because no patients with rs1127354 minor genotype CA/AA had significant anemia.CONCLUSION:Reliable formulae for predicting the likelihood of ribavirin-induced anemia were constructed.Such modeling may be useful in developing individual tailoring and optimization of ribavirin dosage. | Akihito Tsubota Noritomo Shimada Hiroshi Abe Kai Yoshizawa Rie Agata Yoko Yumoto Makiko Ika Yoshihisa Namiki Keisuke Nagatsuma Hiroshi Matsudaira Kiyotaka Fujise Norio Tada Yoshio Aizawa | 2012 | World Journal of Gastroenterology2012，18，41： | 1 |
| 2 | Fiber Bragg grating temperature sensor for practical use显示文摘 | Yasukazu S | 2000 | ISA Transactions2000，39，： | 1 |
| 3 | Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b显示文摘AIM To investigate the influence of interferon-free antivirus therapy on lipid profiles in chronic hepatitis C virus genotype 1b(HCV1b) infection.METHODS Interferon-free antiviral agents were used to treat 276 patients with chronic HCV1 b infection, and changes in serum lipids of those who achieved sustained virologic response(SVR) were examined. The treatment regimen included 24 wk of daclatasvir plus asunaprevir(DCV + ASV) or 12 wk of sofosbuvir plus ledipasvir(SOF + LDV). SVR was achieved in 121(85.8%) of 141 patients treated with DCV + ASV and 132(97.8%) of 135 patients treated with SOF + LDV. In the two patient groups(DCV + ASV-SVR and SOF + LDV-SVR), serum total cholesterol(TC), low-density lipoprotein cholesterol(LDL-C), high-density lipoprotein cholesterol(HDL-C), and triglycerides were measured at baseline during treatment and at 4 and 12 wk after treatment. Then, longitudinal changes in lipid profiles were analyzed.RESULTS Serum levels of TC, LDL-C, and HDL-C were significantly increased throughout the observation period in both the DCV + ASV-SVR and SOF + LDV-SVR groups. During antivirus treatment, the increases in TC and LDL-C were significantly greater in the SOF + LDVSVR group than in the DCV + ASV-SVR group(P < 0.001). At 4 and 12 wk after the therapy, serum levels of TC and LDL-C were similar between the two groups and were significantly greater than those at baseline. Approximately 75%-80% of the increase in TC was derived from an increased LDL-C. In multiple regression analysis, the difference in therapy protocol(DCA + ASV or SOF + LDV) was an independent predictor that was significantly associated with the increase in TC and LDL-C at 4 wk of therapy.CONCLUSION Serum cholesterol significantly increased during SOF + LDV treatment. After treatment, HCV elimination was associated with a similar increase in cholesterol regardless of the therapy protocol. | Daisuke Endo Kenichi Satoh Noritomo Shimada Atsushi Hokari Yoshio Aizawa | 2017 | World Journal of Gastroenterology2017，23，13： | 1 |
| 4 | New proposal for response‐guided peg‐interferon‐plus‐ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection显示文摘 | Hiroshi Abe Yuta Aida Haruya Ishiguro Kai Yoshizawa Nobuyoshi Seki Tamihiro Miyazaki Munenori Itagaki Satoshi Sutoh Makiko Ika Keizo Kato Noritomo Shimada Akihito Tsubota Yoshio Aizawa | 2013 | Virol2013，，9： | 1 |
| 5 | Fiber Bragg Grating Temperature Sensor for Practical Use显示文摘 | Noritomo H Yasukazu S | 2000 | ISA Transactions2000，39，： | 1 |
| 6 | Serum apolipoprotein B‐100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b显示文摘 | Kai Yoshizawa Hiroshi Abe Yuta Aida Haruya Ishiguro Makiko Ika Noritomo Shimada Akihito Tsubota Yoshio Aizawa | 2013 | J. Med. Virol2013，，7： | 1 |
| 7 | An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2010)显示文摘 | Shigeru Nakai Kunitoshi Iseki Noritomo Itami Satoshi Ogata Junichiro James Kazama Naoki Kimata Takashi Shigematsu Toshio Shinoda Tetsuo Shoji Kazuyuki Suzuki Masatomo Taniguchi Kenji Tsuchida Hidetomo Nakamoto Hiroshi Nishi Seiji Hashimoto Takeshi Hasegaw | 2012 | Therapeutic Apheresis and Dialysis2012，，6： | 1 |
| 8 | Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C显示文摘AIM: To evaluate interferon-λ3(IFNL3) polymorphisms in response-guided pegylated interferon-α plus ribavirin(Peg-IFNα/RBV) therapy for genotype 2(G2) chronic hepatitis C.METHODS: Between January 2006 and June 2012, a total of 180 patients with chronic infections of G2 hepatitis C virus(HCV) were treated with responseguided Peg-IFNα/RBV therapy. The treatment duration was 24 wk for patients who achieved rapid virologic response(RVR), and 36 or 48 wk for patients who did not. Then, the impact of the IFNL3 single nucleotide polymorphism genotype(TT/non-TT at rs8099917) on treatment outcomes was evaluated in the 180 patients, and between patients infected with either HCV subgenotype 2a or 2b.RESULTS: Of the 180 patients evaluated, 111 achieved RVR, while the remaining 69 patients did not. In RVR patients, the sustained virologic response(SVR) rate was 96.4%, and the IFNL3 genotype did not influence the SVR rate(96.6% vs 95.8% in IFNL3 genotype TT vs non-TT). However, in non-RVR patients, the SVR rate decreased to 72.5%(P < 0.0001), and this rate was significantly different between the IFNL3 genotype TT and non-TT groups(80.0% vs 42.9%, P = 0.0146). Multivariate regression analysis in non-RVR patients identified the IFNL3 genotype TT as the only baseline-significant factor associated with SVR(OR = 5.39, 95%CI: 1.29-22.62; P = 0.0189). In analysis according to HCV sub-genotype, no significant difference in the SVR rate was found between HCV sub-genotypes 2a and 2b.CONCLUSION: In response-guided Peg-IFNα/RBV combination therapy for chronically HCV G2-infected patients, the impact of the IFNL3 genotype on SVR was limited to non-RVR patients. | Haruya Ishiguro Hiroshi Abe Nobuyoshi Seki Tomonori Sugita Yuta Aida Munenori Itagaki Satoshi Sutoh Noritomo Shimada Tomomi Furihata Akihito Tsubota Yoshio Aizawa | 2015 | World Journal of Gastroenterology2015，21，13： | 0 |
| 9 | 雷莫芦单抗用于经乐伐替尼治疗后进展的不可切除肝细胞癌的治疗效果显示文摘背景:在日本,乐伐替尼可用于不可切除原发性肝癌的一线、二线或三线治疗。本研究评估新近研发的雷莫芦单抗用于经乐伐替尼治疗后进展的不可切除的原发性肝癌的疗效。方法:2018年5月至2020年1月间在日本16家中心接受乐伐替尼治疗的385例不可切除原发性肝癌患者中,我们将其中接受雷莫芦单抗作为下一线治疗的28例患者纳入研究,对其治疗效果进行回顾性分析。结果:28例患者中位年龄70岁,中位白蛋白-胆红素(ALBI)评分为2.19。28例患者中,23例为男性;21例为Child-Pugh A级,7例为Child-Pugh B级;3例为BCLC B期,25例为BCLC C期。雷莫芦单抗用于二线、三线和四线治疗的病例分别为14例、9例和5例患者。26例患者获得疗效评估,客观缓解率为3.8%(1/26),疾病控制率为42.3%(11/26);中位疾病进展时间为2个月。未继续接受雷莫芦单抗治疗的原因包括16例出现疾病进展和2例出现3级不良反应(消化道出血和腹水)。结论:我们的初步研究显示,对于乐伐替尼治疗进展的不可切除原发性肝癌,雷莫芦单抗并没有获得预期的治疗效果。 | Atsushi Hiraoka Takashi Kumada Toshifumi Tada Chikara Ogawa Joji Tani Shinya Fukunishi Masanori Atsukawa Masashi Hirooka Kunihiko Tsuji Toru Ishikawa Koichi Takaguchi Kazuya Kariyama Ei Itobayashi Kazuto Tajiri Noritomo Shimada Hiroshi Shibata Hironori Ochi Kazuhito Kawata Hidenori Toyoda Hideko Ohama Kazuhiro Nouso Akemi Tsutsui Takuya Nagano Norio Itokawa Korenobu Hayama Taeang Arai Michitaka Imai Yohei Koizumi Shinichiro Nakamura Kojiro Michitaka Yoichi Hiasa Masatoshi Kudo | 2021 | Gastroenterology Report2021，9，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员